Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 23, 2017. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director or Manager (PDMR), rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £15.97 per share.
- Transaction Volume: 370 shares.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an acquisition of shares by Dr. S. Dexter, a PCA of Dr. P. J. T. V. Allance (President, R&D).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was an acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on January 12, 2017, executed on the London Stock Exchange on January 16, 2017.
Investor Verification Checklist
- Verify the identity of Dr. S. Dexter and their relationship to Dr. P. J. T. V. Allance.
- Confirm the dividend reinvestment plan details for the January 12, 2017 payment date.
- Check the London Stock Exchange (XLON) records for the transaction executed on January 16, 2017.
- Note that this filing does not contain quarterly or annual financial performance data.